Brief: Ideaya Biosciences Announces Phase 1/2 Expansion For Ide397 And Trodelvy® Combination In Mtap-Deletion Urothelial Cancer
10/04/2025 11:02
April 10 (Reuters) - IDEAYA Biosciences Inc IDYA.O: IDEAYA BIOSCIENCES ANNOUNCES PHASE 1/2 EXPANSION FOR IDE397 AND TRODELVY® COMBINATION IN MTAP-DELETION UROTHELIAL CANCER IDEAYA BIOSCIENCES INC - CLINICAL PROGRAM UPDATE ON IDE397 AND TRODELVY COMBINATION PLANNED IN 2025 IDEAYA BIOSCIENCES INC - TO INITIATE TRIAL OF IDE397 AND IDE892 IN H2 2025 Source text: ID:nPn9b3fRqa Further company coverage: IDYA.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on IDEAYA Biosciences
See all newsBrief: Ideaya Biosciences And Servier Announce Data From Three Clinical Trials At Esmo 2026 Supporting The Potential Of Darovasertib To Become A Foundational New Therapy For Patients Across The Treatment Journey Of Uveal Melanoma
Brief: Ideaya Biosciences Announces The Promotion Of Dr. Michael White To President, Research And Development
Brief: Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Ideaya Biosciences Inc Reports Results For The Quarter Ended June 30: Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj